| FNGR 0.398 129.53% | CHAI 0.4 57.11% | LGCL 0.0389 -27.02% | CYAB 0.4467 45.36% | NVDA 217.55 -4.57% | CHGA 2.852 2,082.10% | PCG 16.6 -7.52% | NCPL 0.6916 28.41% | NVD 4.05 8.58% | BITO 10.45 -3.06% | IREN 35.45 -12.53% | INTC 89.47 -2.85% | NU 14.3 -3.90% | IBIT 43.9 -3.07% | XTNT 0.384 16.36% | TSLL 8.98 -3.54% | ONDS 7.9 -9.71% | DUO 0.9602 37.56% | AAL 13.64 -0.58% | SOAR 0.2169 5.80% | SOXL 111.34 -9.52% | BTAI 0.1814 -74.76% | TQQQ 71.85 -1.98% | ETHA 18.37 -2.65% | FTFT 2.2188 281.50% | SPCX 141.5 0.45% | PATH 18.15 -0.98% | BMNR 23.8 -7.14% | NOK 10.21 -3.59% | AMZN 266.43 3.97% | MRVL 216.62 -10.28% | SOXS 49.82 9.86% | WHLR 1.07 -4.46% | SQQQ 38.54 2.03% | PLUG 2.19 -3.52% | SOFI 18.06 -5.84% | AEMD 2.49 14.75% | SPDN 8.49 0.12% | QID 14.24 1.42% | MARA 10.67 -10.11% | KEEL 3.23 -7.98% | GDX 99.65 -3.90% | RIVN 16.07 -4.35% | F 13.87 -0.57% | BTG 5.66 -2.92% | AAPL 319.7 1.63% | PURR 11.61 -9.51% | SMR 9.29 -4.62% | VALE 15.03 -1.83% | SPY 769.35 -0.23%

Neogen Corporation's Financial Performance and Strategic Moves

Neogen Corporation, trading under NASDAQ:NEOG, is a prominent player in the food and animal safety industry. The company focuses on developing and marketing products dedicated to food safety, animal safety, and genomics. Neogen's competitors include companies like IDEXX Laboratories and Zoetis. Recently, Nassif Mikheal, the director and CEO, purchased 137 shares at $9.33 each, increasing his total holdings to 632 shares.

Neogen's recent financial performance has been noteworthy. The company reported second-quarter fiscal 2026 earnings per share (EPS) of 10 cents and revenues of $224.7 million, both surpassing expectations. This strong performance led to a 31.6% increase in the stock price, as highlighted by Barron's. Despite a 2.8% year-over-year revenue decrease, core revenues grew by 2.9%, offsetting declines from divestitures and discontinued products.

The company has raised its fiscal 2026 guidance, projecting revenues between $845 million and $855 million, with approximately $175 million in adjusted EBITDA. The positive impact of foreign currency contributed 0.9% to the revenue, while divestitures and discontinued product lines negatively impacted it by 6.6%. Neogen's results exceeded the Zacks Consensus Estimate by 7.93%, indicating strong performance and an optimistic outlook.

Neogen's financial metrics reveal a mixed picture. The price-to-sales ratio is approximately 2.35, and the enterprise value to sales ratio is about 3.09, suggesting the market values the company's sales and total valuation, including debt, at a premium. The enterprise value to operating cash flow ratio is high at 41.08, indicating a premium relative to cash flow generation. The debt-to-equity ratio is 0.38, reflecting a low level of debt compared to equity.

The company maintains a strong liquidity position with a current ratio of approximately 3.91, indicating ample current assets to cover liabilities. Neogen's strategic initiatives and strong market position continue to drive investor confidence, as evidenced by the recent stock price surge following the earnings report.

Published on: January 16, 2026